CXCL8 and hepatocellular carcinoma: In partial agreement with our results, a meta-analysis has explored the roles of IL-8 rs2227306 SNP and cancer risk in 22 case-control studies; they identified a significant decrease of hepatocellular carcinoma risk with IL-8 rs2227306T/C polymorphism (OR = 0.72, 95% CI = 0.56–0.91, p = 0.007∗) [28].